Category - Markets

Ladenburg Thalmann launched coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $6.25 price target. The stock closed at $1.43 on Sept. 6. “We believe CYC065, the company’s CDK 2/9 inhibitor, has...

Roth Capital Partners initiated coverage of Obalon Therapeutics (NASDAQ:OBLN) with a “buy” rating and $6 price target. The stock closed at $2.91 on Sept. 5. Obalon offers the Obalon Balloon System, the first and only...

Piper Jaffray resumed coverage of Bovie Medical (NYSE American:BVX) with an “overweight” rating and $8 price target after the company completed the sale of its core business. The stock finished at $6.14 on Sept. 5...

H.C. Wainwright lowered its price target for Histogenics (NASDAQ:HSGX) to $2 from $3.50, but maintained its “buy” rating, after the company missed its primary endpoint in a Phase 3 study of NeoCart for knee cartilage...

Roth Capital Partners launched coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $8 price target. The stock closed at $1.57 on September 4. “We believe that Cyclacel, its clinical CDK inhibitor...

Analysts at BTIG and Ladenburg Thalmann initiated coverage of Vaccinex (NASDAQ:VCNX) with “buy” ratings and price targets of $20 and $22, respectively. The stock closed at $9.99 on August 31. Vaccinex, which went public...

H.C. Wainwright initiated coverage of Immune Design (NASDAQ:IMDZ) with a “buy” rating and $11 price target. The stock closed at $3.45 on August 29. “Based on our broad and long-term coverage of cancer immunotherapy, we...

H.C. Wainwright raised its price target for Sophiris Bio (NASDAQ:SPHS) to $10 from $4.30, citing autopsy results that found a patient deathin its Phase 2b trial for the treatment of localized prostate cancer was not...

H.C. Wainwright initiated coverage of Coherus BioSciences (NASDAQ:CHRS) with a “buy” rating and $28 price target. The stock closed at $19.75 on August 27. “We expect approval of UDENCYA, CHS-1701, in both the U.S. and...

Stifel upgraded Capital Senior Living (NYSE:CSU) to “hold” from “sell” but maintained its price target of $8.50, saying the shares have overshot its fair value estimates. The stock closed at $8.34 on August 23. “We...